10.00 - 12.00
CLINICAL STUDIES
12.30 - 12.35
WELCOME ADDRESS
Prof. Monika Długosz-Danecka, Prof. Wojciech Jurczak, Prof. Lidia Gil, Prof. Iwona Hus
12.35 - 14.10
SESSION 1 | HODGKIN’S LYMPHOMA
Chairpersons: Prof. Monika Długosz-Danecka, Prof. Grzegorz Basak
12.35 - 13.00
How much chemotherapy do we need in HL? | Dr Stephen Ansell (lecture in English, translation available)
13.00 - 13.15
Sponsored lecture
13.15 - 13.30
Sponsored lecture
13.30 - 13.45
The role of allogeneic transplants in HL and T-cell lymphomas | Prof. Grzegorz Basak
13.45 - 14.10
Debate: Treatment for refractory/relapsing HL depends on the choice of first-line regimen | Prof. Monika Długosz-Danecka, Dr hab. Elżbieta Kalicińska, Prof. Grzegorz Basak, Prof. Marcin Pasiarski, Dr Stephen Ansell
14.10 - 14.25
Coffee break
14.25 - 16.00
SESSION 2 | INDOLENT B-CELL LYMPHOMAS
Chairpersons: Prof. Ewa Lech-Marańda, Prof. Wojciech Jurczak
14.25 - 14.50
“Chemo or no chemo” as a future SOC in indolent lymphoma | Dr Pavel Klener (lecture in English, translation available)
14.50 - 15.05
Sponsored lecture
15.05 - 15.20
Sponsored lecture
15.20 - 15.35
Will degraders replace iBTK in indolent lymphomas | Prof. Ewa Lech-Marańda
15.35 - 16.00
Debate: How to optimally use immunotherapy and molecularly targeted therapy in indolent lymphomas? | Prof. Ewa Lech-Marańda, Dr hab. Marta Morawska, Dr hab. Joanna Romejko-Jarosińska, Prof. Wojciech Jurczak, Dr Pavel Klener
16.00 - 16.15
Coffee break
16.15 - 17.50
SESSION 3 | AGGRESSIVE LYMPHOMAS
Chairpersons: Prof. Monika Długosz-Danecka, Prof. Grzegorz Basak
16.15 - 16.40
Lenalidomide and beyond | Prof. Grzegorz Nowakowski (lecture in English, translation available)
16.40 - 16.55
Everything starts with the first-line treatment. Treatment standards and specific situations | Prof. Wojciech Jurczak
16.55 - 17.10
Sponsored lecture
17.10 - 17.25
Sponsored lecture
17.25 - 17.50
Debate: Alternatives to T-cell engagers | Dr hab. Katarzyna Brzeźniakiewicz-Janus, Prof. Wojciech Jurczak, Prof. Grzegorz Nowakowski, Prof. Tomasz Wróbel